KLOW 80mg

KLOW is a research tetra-peptide blend in a single 80 mg lyophilized vial that combines two tissue-repair peptides (BPC-157 and TB-500), an α-MSH-derived anti-inflammatory tripeptide (KPV), and a copper tripeptide for dermal remodeling (GHK-Cu). The literature describes complementary pathways of angiogenesis, immune modulation, and extracellular matrix synthesis in experimental models.

Blend composition (80 mg lyophilized per vial):

• BPC-157 (10 mg): pentadecapeptide derived from a gastric juice protective sequence. Preclinical literature documents upregulation of VEGFR2 (angiogenesis) and repair of tendon, ligament, and mucosa in murine models. Vasireddi N et al., Am J Sports Med 2025 (PMID 40756949) review 36 studies on the modulation of tissue repair pathways.
• TB-500 (10 mg): Synthetic fragment (LKKTETQ) of Thymosin Beta-4. Literature documents cell migration, angiogenesis via AC-SDKP, and cytokine modulation. Crockford D et al., Ann N Y Acad Sci 2010 (PMID 20955331) y Sosne G et al., Exp Eye Res 2002 (PMID 11819014) in healing models.
• KPV (10 mg): The Lys-Pro-Val tripeptide, derived from the C-terminal end of α-MSH. Literature documents an anti-inflammatory effect via PepT1 transport in colitis models. Dalmasso G et al., Gastroenterology 2008 (PMID 18061177).
• GHK-Cu (50 mg): Gly-His-Lys tripeptide complexed with copper (II). Literature describes synthesis of type I/III collagen, extracellular matrix modulation, antioxidant activity, and suppression of TGF-β1. Pickart L, Margolina A, Int J Mol Sci 2018 (PMID 30041448) Review the dermatologic remodeling.

• BPC-157 (10 mg): pentadecapeptide derived from a gastric juice protective sequence. Preclinical literature documents upregulation of VEGFR2 (angiogenesis) and repair of tendon, ligament, and mucosa in murine models. Vasireddi N et al., Am J Sports Med 2025 (PMID 40756949) review 36 studies on the modulation of tissue repair pathways.
• TB-500 (10 mg): Synthetic fragment (LKKTETQ) of Thymosin Beta-4. Literature documents cell migration, angiogenesis via AC-SDKP, and cytokine modulation. Crockford D et al., Ann N Y Acad Sci 2010 (PMID 20955331) y Sosne G et al., Exp Eye Res 2002 (PMID 11819014) in healing models.
• KPV (10 mg): The Lys-Pro-Val tripeptide, derived from the C-terminal end of α-MSH. Literature documents an anti-inflammatory effect via PepT1 transport in colitis models. Dalmasso G et al., Gastroenterology 2008 (PMID 18061177).
• GHK-Cu (50 mg): Gly-His-Lys tripeptide complexed with copper (II). Literature describes synthesis of type I/III collagen, extracellular matrix modulation, antioxidant activity, and suppression of TGF-β1. Pickart L, Margolina A, Int J Mol Sci 2018 (PMID 30041448) Review the dermatologic remodeling.

Research material only. No FDA-approved human use. Information is provided for educational and scientific literature reference purposes.

• Total: 80 mg lyophilized per vial
• Purity >98% by HPLC (each component)
• Laboratory reconstitution: 2 ml bacteriostatic water → 40,000 mcg/ml total solution (5,000 BPC + 5,000 TB + 5,000 KPV + 25,000 GHK per ml)
• Conservation lyophilized refrigerated 2-8°C protect from light (photosensitive copper complex) use within 28 days after reconstitution
• Aspect pale sky-blue lyophilized powder (color characteristic of complexed copper)

Material intended exclusively for scientific research.

Not for human consumption. No FDA-approved human use. Information is provided for educational and reference purposes to the published scientific literature.